secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001171843-25-003326
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose doses first patient at 120 mg tuspetinib in TUSCANY triplet trial after positive safety review
--------------------------------------------------------------------------------

- CSRC cleared escalation to 120 mg TUS based on safety from 40 mg and 80 mg cohorts.
- First patient dosed at 120 mg as part of TUS+VEN+AZA triplet frontline therapy for AML.
- No prolonged myelosuppression or dose-limiting toxicities reported in first two cohorts.
- Complete remissions and MRD negativity observed across diverse AML mutations.
- Updated data to be presented at EHA 2025 congress (June 12-15) in Milan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003326/0001171843-25-003326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003326/f8k_051925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer